Nociceptin is Present in Synovial Fluid of Patients Undergoing Total Knee Arthroplasty

CURRENT STATUS: Under Review

Thomas Verbeek, Nancy Ruth Jarbadan, Charles Davis, Julia Caldwell

Thomas Verbeek
Pennsylvania State University
Corresponding Author
ORCiD: https://orcid.org/0000-0002-7663-1656

Nancy Ruth Jarbadan
Penn State College of Medicine

Charles Davis
Penn State Health Milton S Hershey Medical Center

Julia Caldwell
Vitality Group

Keywords

Orthopedic Surgery Orthopedics
Nociceptin, Orphanin FQ, Osteoarthritis, Neuroinflammation, Arthroplasty
Abstract

Background

Nociceptin, an endogenous neuropeptide with similar structure to classical opioids, is involved in a variety of systemic modulatory responses. Osteoarthritis, a chronic neuroinflammatory condition, appears to have both pro- and anti-inflammatory processes that are possibly linked to nociceptin. The presence of nociceptin in human synovial fluid has been documented in some studies; however, in others it was not detected. The goal of this pilot study was to determine whether nociceptin was present in the synovial fluid of osteoarthritic knees.

Methods

Patients undergoing primary total knee arthroplasty were enrolled after Institutional Review Board approval was obtained. Synovial fluid was aspirated from patients’ operative knee joints and blood samples were obtained. A commercially available enzyme Immunoassay kit was used to test for nociceptin. A linear mixed-effects model was developed to account for the repeated measurements and baseline covariates. Least squares (adjusted) means were derived from the model to compare the sample types and to compare subgroups.

Results

Twenty patients were included in this study. Nociceptin was detected in the synovial fluid and plasma of all patients. The mean concentration (± standard deviation) of nociceptin in synovial fluid was 28.7 ± 18.2 pg/ml. The mean concentration of nociceptin in plasma were 45.2 ± 24.3 pg/ml pre-procedure, and 40.1 ± 20.6 pg/ml post-tourniquet deflation. The nociceptin concentration in synovial fluid was significantly lower than the nociceptin concentration in plasma, both pre-procedure and post-tourniquet deflation (p=0.002 and p=0.016 respectively). The nociceptin concentration in both plasma and synovial fluid was significantly lower in females versus males (p=0.012).

Conclusion

We demonstrated that nociceptin is present in synovial fluid and plasma of patients undergoing total knee arthroplasty. This implies a potential role for nociceptin in modulating inflammation in osteoarthritis.

Trial registration

ClinicalTrials.gov, NCT02528916. Retrospectively registered on 19 August 2015, https://clinicaltrials.gov/ct2/show/NCT02528916

Background

Nociceptin is a neuropeptide with similar structure to endogenous opioids. It lacks agonistic activity at classical opioid receptors (mu, kappa, and delta) and resists naloxone-induced antagonism. Neuroinflammation is a process mediated by peripheral release of sensory neuropeptides from nerve terminals, and appears to utilize nociceptin for both pro- and anti-inflammatory effects. Osteoarthritis is a mechanical abnormality characterized by chronic joint pain associated with degeneration of the articular cartilage, synovitis, and local inflammation. Some studies indicate that nociceptin can be measured in synovial fluid, while other studies indicate that it cannot be detected. The goal of this pilot study was to determine whether nociceptin was present in the synovial fluid of osteoarthritic knees. These data will be used to design a study comparing healthy subjects’ synovial fluid and plasma nociceptin concentrations to the same measurements in patients with osteoarthritis.
Methods

The study was registered retrospectively with ClinicalTrials.gov (registration number NCT02528916). EQUATOR guidelines for a cross-sectional observational study were followed. Twenty-two patients were enrolled between May and November 2014. This was a convenience sample of patients aged 18–80 years, diagnosed with osteoarthritis, undergoing primary total knee arthroplasty (TKA). Patients who were not hemodynamically stable, had undergone prior joint arthroplasty at the current surgical site, or had active infection of their knee joint, were excluded from the study. The same orthopedic surgeon performed all of the procedures. Anesthetic technique consisted of general anesthesia combined with regional anesthesia (femoral nerve block, subarachnoid block, or lumbar epidural). Standard institutional anesthetic technique was followed.

Two blood samples (3 ml each from the antecubital vein) and a synovial fluid sample (5 ml) were obtained from each patient. The first blood sample was collected pre-operatively, during intravenous catheter placement. After induction of anesthesia, a tourniquet was applied to the operative thigh to limit blood loss and to ensure a dry operative field. The synovial fluid sample was aspirated from the knee joint after skin incision, and the second blood sample was collected five minutes after the thigh tourniquet was deflated. Blood samples were collected in BD Vacutainer K2 EDTA Plus Blood Collection Tubes (BD, Franklin Lakes, New Jersey, USA) and placed on ice until processed by the addition of the protease inhibitor aprotinin and centrifugation (1600 x g, 4°C, 15 min). The plasma supernatant was aliquoted into RNAse/DNAse-free tubes and stored at -80°C until assayed. Synovial fluid was collected, aliquoted, and stored at -80 °C until assayed. The concentration of nociceptin in plasma and synovial fluid was quantified by fluorescent enzyme immunoassay using the nociceptin/orphanin FQ enzyme immunoassay kit from Phoenix Pharmaceuticals, Burlingame, California, USA.

Additional patient information, including patient age, gender, and body mass index, was collected. Patient-reported pre- and postoperative pain was assessed using an eleven-point Numerical Rating Scale (NRS)\textsuperscript{10}. Preoperative pain was assessed on admission. Post-procedure pain was assessed as the first pain NRS score provided by the patient in the post-anesthesia recovery unit. The patient’s status according to the American Society of Anesthesiologists (ASA) Physical Status Classification System was recorded.

Study data were collected and managed using REDCap (Research Electronic Data Capture) electronic data capture tools hosted at Penn State Health Milton S. Hershey Medical Center.\textsuperscript{11} Data were analyzed using SAS\textsuperscript{®} software, Version 9.4 (SAS Institute Inc., Cary, North Carolina, USA). A linear mixed-effects model was developed to account for the repeated measurements and baseline covariates. Least squares (adjusted) means were derived from the model to compare the sample types and to compare subgroups, such as males versus females. P values less than 0.05 were considered statistically significant.

Results

Twenty-two patients with clinically diagnosed osteoarthritis were enrolled. Technical reasons prevented us from obtaining synovial fluid samples from two patients – they were excluded from the analysis. Demographic data for the patient population are shown in Table 1.
Sixteen patients received general anesthesia plus ultrasound guided femoral nerve blocks with a long-acting local anesthetic (7 males, 9 females). Three patients underwent the procedure with continuous lumbar epidural anesthesia combined with general anesthesia (2 females and 1 male). These three participants underwent bilateral total knee replacements. In these patients, synovial fluid samples were obtained from the first joint operated on only, and plasma samples were obtained after release of the first tourniquet. One female patient received subarachnoid anesthesia combined with general anesthesia, and had a femoral nerve block after the procedure. Nociceptin was detected in all plasma and synovial fluid samples (Table 2).

Table 2
Nociceptin is Present in Synovial Fluid and Plasma.

|                     | Pre-procedure (Plasma) | Post-tourniquet release (Plasma) | Synovial Fluid |
|---------------------|------------------------|---------------------------------|---------------|
| Nociceptin concentration (pg/ml)* | 45.2 ± 24.3            | 40.1 ± 20.6                    | 28.7 ± 18.2   |
| Range (pg/ml)       | 7.5 to 120.7           | 9.0 to 104.0                   | 5.2 to 123.6  |

*Data are presented as mean ± standard deviation.

The nociceptin concentration in synovial fluid (28.7 ± 18.2 pg/ml) was significantly lower than the nociceptin concentrations in plasma, both pre-procedure (p = 0.002) and post-tourniquet deflation (p = 0.016). The difference in nociceptin plasma concentrations pre-procedure and post-tourniquet deflation was not statistically significant (p = 0.34).

There was no significant correlation between nociceptin levels and age (p = 0.12), Body Mass Index (p = 0.23), pre-operative pain scores (p = 0.53) or post-operative pain scores (p = 0.36). However, there was a significant correlation between nociceptin levels and gender (p = 0.012). The nociceptin concentration in plasma and synovial fluid was significantly higher in males than in females (Table 3).
Table 3

Nociceptin Concentrations in Males versus Females.

| Sample                        | Male Nociceptin Concentration (pg/ml)* | Female Nociceptin Concentration (pg/ml)* | P value  |
|-------------------------------|---------------------------------------|------------------------------------------|----------|
| Pre-procedure (Plasma)        | 60.5 ± 16.0                           | 47.5 ± 18.6                              | 0.035    |
| Post-tourniquet release (Plasma) | 55.7 ± 14.3                           | 42.2 ± 16.7                              | 0.016    |
| Synovial Fluid                | 48.3 ± 20.7                           | 26.0 ± 9.4                               | 0.0008   |

Data are presented as mean ± standard deviation.

Discussion

We demonstrated measurable levels of nociceptin in both the plasma and synovial fluid of osteoarthritis patients undergoing knee arthroplasty. The detection of nociceptin in synovial fluid is qualitatively similar to the results of Fiset, et al.², although quantitatively we found nociceptin concentrations that were orders of magnitude lower. Our results also contrast with the report of Kumar, et al.⁹, where nociceptin was not detected in synovial fluid, however, our processing and assay methods differed from those used in Kumar’s study.

We detected nociceptin in plasma, while Fiset, et al. did not detect nociceptin in autologous plasma samples². We used freshly harvested patient samples that were immediately processed and then analyzed within a few days to a few months, whereas Fiset, et al. used banked synovial fluid and plasma samples. These differences may have contributed to the discrepancies noted. Our results for nociceptin concentrations in plasma are consistent with plasma nociceptin concentrations of 9.6 ± 2.6 pg/ml and 10.7 ± 5.6 pg/ml reported by Ertsey, et al., and Ko, et al., respectively, for healthy controls.¹²,¹³

There was no control group. Our goal with this study was to determine if nociceptin was present or absent in synovial fluid, making a control group unnecessary. We did not obtain a synovial fluid sample from subjects’ contralateral knees as this was deemed an unacceptable risk to the patient.

Given the exploratory nature of this pilot study consisting of only 20 subjects, one cannot place undue significance on results obtained when analyzing subgroups. However, the p value of 0.0008, for the difference in synovial fluid nociceptin concentration between males and females, suggests a difference that warrants further investigation. Abundant evidence indicates greater pain sensitivity among females compared with males.¹⁴ Holtzman, et al. reported that women were more likely to report severe pain and disability when presenting for total hip replacement surgery than their male counterparts¹⁵. Srikanth, et al. showed that females tended to have more severe osteoarthritis in the knee compared to males¹⁶. More research is needed to clarify this possible association between lower levels of nociceptin in synovial fluid and increased osteoarthritis in females.

In conclusion, nociceptin is present in the synovial fluid of patients undergoing primary knee arthroplasty. This implies a potential role for nociceptin in modulating inflammation in osteoarthritis.

Abbreviations

TKA
Total Knee Arthroplasty

NRS

Numerical Rating Scale

ASA

American Society of Anesthesiologists

REDCap

Research Electronic Data Capture

** Declarations**

**Ethics approval and consent to participate**

Institutional Review Board approval was received prior to initiation of the study (reference number 42679) and written informed consent was obtained from all participants.

**Consent for publication**

N/A

**Availability of data and material**

The datasets generated and analyzed during the current study are available from the corresponding author on reasonable request.

**Competing interests**

None of the authors report any conflict of interest.

**Funding**

This project was funded by the Department of Anesthesiology & Perioperative Medicine, Penn State Health Milton S. Hershey Medical Center. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

**Authors’ contributions**

Study design: J.C., N.R.J., C.D., T.A.V.

Patient recruitment: J.C., N.R.J.

Data collection: J.C., N.R.J., C.D., T.A.V.

Data analysis: J.C., T.A.V.

Manuscript writing: J.C., N.R.J., C.D., T.A.V.

**Acknowledgements**

Special thanks to Vernon Chinchilli, Ph.D., Distinguished Professor, Division of Biostatistics and Bioinformatics and Chair, Public Health Sciences, Penn State College of Medicine, for his statistical analysis; to Diane McCloskey, Ph.D., Research Specialist, Department of Anesthesiology & Perioperative Medicine, Penn State
College of Medicine, for scientific editing and manuscript preparation; to Dr. Sonia Vaida, M.D., as well as Dr. Dmitri Bezinover, M.D., Ph.D. for their encouragement throughout the project; and to Victor Ruiz-Velasco, Ph.D. for his invaluable help during the submission process. We also want to thank Jonathan B. Derr, MS, MBA, Matthew J. McClain, MD, Alexander J. Skojec, MD, and Arissa M. Torrie, MD, MHS for their contributions to this project.

References

1. Meunier JC, Mollereau C, Toll L, et al. Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature. 1995;377:532–5.
2. Fiset ME, Gilbert C, Poubelle PE, Pouliot M. Human neutrophils as a source of nociceptin: a novel link between pain and inflammation. Biochemistry. 2003;42:10498–505.
3. Mathis JP, Mandyam CD, Altememi GF, Pasternak GW, Standifer KM. Orphanin FQ/nociceptin and naloxone benzoylehydrazone activate distinct receptors in BE(2)-C human neuroblastoma cells. Neurosci Lett. 2001;299:173–6.
4. Mamiya T, Noda Y, Ren X, et al. Morphine tolerance and dependence in the nociceptin receptor knockout mice. J Neural Transm (Vienna). 2001;108:1349–61.
5. Meunier JC. Utilizing functional genomics to identify new pain treatments: the example of nociceptin. Am J Pharmacogenomics. 2003;3:117–30.
6. Inoue M, Kobayashi M, Kozaki S, Zimmerman A, Ueda H. Nociceptin/orphanin FQ-induced nociceptive responses through substance P release from peripheral nerve endings in mice. Proc Natl Acad Sci U S A. 1998;95:10949–53.
7. Helyes Z, Németh J, Pintér E, Szolcsányi J. Inhibition by nociceptin of neurogenic inflammation and the release of SP and CGRP from sensory nerve terminals. Br J Pharmacol. 1997;121:613–5.
8. Pereira D, Peleteiro B, Araújo J, Branco J, Santos RA, Ramos E. The effect of osteoarthritis definition on prevalence and incidence estimates: a systematic review. Osteoarthritis Cartilage. 2011;19:1270–85.
9. Kumar N, Smart D, Mason S, McKnight AT, Rowbotham DJ, Lambert DG. Neither nociceptin nor its receptor are present in human synovial fluid or tissue. Br J Anaesth. 1999;83:470–1.
10. Breivik H, Borchgrevink PC, Allen SM, et al. Assessment of pain. Br J Anaesth. 2008;101:17–24.
11. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377–81.
12. Ertsey C, Hantos M, Bozsik G, Tekes K. Circulating nociceptin levels during the cluster headache period. Cephalalgia. 2004;24:280–3.
13. Ko MH, Kim YH, Woo RS, Kim KW. Quantitative analysis of nociceptin in blood of patients with acute and chronic pain. Neuroreport. 2002;13:1631–3.
14. Fillingim RB, King CD, Ribeiro-Dasilva MC, Rahim-Williams B, Riley JL 3. Sex, gender, and pain: a review of recent clinical and experimental findings. The journal of pain: official journal of the American Pain Society. 2009;10:447–85. rd .
15. Holtzman J, Saleh K, Kane R. Gender differences in functional status and pain in a Medicare population undergoing elective total hip arthroplasty. Med Care. 2002;40:461–70.
16. Srikanth VK, Fryer J, Zhai G, Winzenberg TM, Hosmer D, Jones G. A meta-analysis of sex differences prevalence, incidence and severity of osteoarthritis. Osteoarthritis Cartilage. 2005;13:769–81.